Diabetes Meds Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Question | Answer |
Biguanide | Metformin - Target is the liver to reduce overproduction of glucose. Max effective dose 2000mg/day |
Sulfonyureas | Glimeperide/amaryl, Glipizide/glucotrol (has xr), Glyburide/diabeta;micronase Target beta cells in pancreas to increase secretion |
Sulfonylureas | Increase insulin secretion, take 30 min before meal |
Metformin Side Effects | GI (nausea/diarrhea), R/F lactic acidosis; monitor Creatinine as it is cleared by kidneys (avoid in women if >1.4, men if >1.5) |
Metformin Advantages | Cost, no weight gain, reduces LDL & Triglycerides, low r/f hypos |
Glimeperide | Sulfonylurea, increase insulin secretion |
Glipizide | Sulfonylurea, increase insulin secretion, comes in XR too |
Glyburide | Sulfonylurea, increase insulin secretion |
Sulfonylurea side effects | R/F hypoglycemia, do not skip meals, Weight gain (1-2kg) |
Thiazolidiones (TZD's) | Pioglitizone/actos; Rosiglitazone/avandia. Targets muscles & liver, insulin sensitizer. Takes 8-12 weeks for full effect, take w/o regard to meals |
Actos (pioglitazone) | TZD, insulin sensitizer, taken daily, low r/f hypo |
Avandia (rosiglitazone) | TZD, insulin sensitizer, taken daily or BID, low r/f hypo |
TZD side effects | Fluid retention/edema, weight gain common (water retention + increase fat mass), fractures r/t slowing of protein building in bone, low r/f bladder ca |
DPP IV Inhibitors | Sitagliptin/januvia, Saxagliptin/onglyza, Linagliptin/tradjenta, Alogliptin/nesina. Targets gut & pancreas. Inhibits glucagon release, stimulates insulin release, delays gastric emptying |
Sitagliptin/januvia | DPP IV Inhibitor. Targets gut & pancreas. Inhibits glucagon release, stimulates insulin release, delays gastric emptying |
Saxagliptin/onglyza | DPP IV Inhibitor. Targets gut & pancreas. Inhibits glucagon release, stimulates insulin release, delays gastric emptying |
Linagliptin/tradjenta | DPP IV Inhibitor. Targets gut & pancreas. Inhibits glucagon release, stimulates insulin release, delays gastric emptying |
Alogliptin/nesina | DPP IV Inhibitor. Targets gut & pancreas. Inhibits glucagon release, stimulates insulin release, delays gastric emptying |
DPP IV Inhibitor side effects | Consider renal adjustments based upon Creatinine clearance |
DPP IV Inhibitor advantages | No weight gain, low r/f hypoglycemia, usually no n/v, oral |
GLP-1 | Exenatide/byetta & bydureon ER, Liraglutide/victoza, Albiglutide/tanzeum, Dulaglutide/trulicity. Targets pancreas & gut to stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying/increased satiety. Injectable |
Exenatide/byetta&bydureon(er) | INJECTABLE. Targets pancreas & gut to stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying/increased satiety. |
Liraglutide/victoza | INJECTABLE. Targets pancreas & gut to stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying/increased satiety. |
Albiglutide/tanzeum | INJECTABLE. Targets pancreas & gut to stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying/increased satiety. |
Dulaglutide/trulicity | INJECTABLE. Targets pancreas & gut to stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying/increased satiety. |
GLP-1 Advantages | Daily and weekly injection options, weight friendly |
GLP-1 side effects | N/V/D, hypoglycemia, slows absorption of other drugs |
SGLT2 Inhibitors | Canagliflozin/invokana, Dapagliflozin/farxiga, Empagliflozin/jardiance. Targets proximal tubule inhibiting glucose reabsorption & increasing glycosuria. |
Canagliflozin/invokana | Targets proximal tubule inhibiting glucose reabsorption & increasing glycosuria. 100-300mg daily |
Dapagliflozin/farxiga | Targets proximal tubule inhibiting glucose reabsorption & increasing glycosuria. 5-10mg daily |
Empagliflozin/jardiance | Targets proximal tubule inhibiting glucose reabsorption & increasing glycosuria. 10-25mg daily |
SGLT2 Inhibitor side effects | Genital mycotic infections, primarily in females & uncircumcised males. Osmotic diuresis |
Amylin Analog | Pramlintide/symlin. Targets pancreas, liver, gut to suppress glucagon secretion, decrease hepatic glucose output, slow gastric emptying. INJECTABLE taken prior to major meals |
Pramlintide/symlin | Amylin Analog, given in conjunction with insulin. Decrease preprandial insulin by 50% at initiation. If Type 1DM 15mcg-60mcg, 4step titration, if Type 2 DM 60mcg-120mcg, 2step titration. Increase dose every 3-7 days depending on GI tolerance. |
AGI's (alpha-glucosidase inhibitors) | Acarbose/precose, Miglitol/glyset. Target gut enzymes, delays carbohydrate absorption due to inhibition of enzymes. |
Acarbose/precose | AGI. Target gut enzymes, delays carbohydrate absorption due to inhibition of enzymes. |
Miglitol/glyset | AGI. Target gut enzymes, delays carbohydrate absorption due to inhibition of enzymes. |
AGI side effects | Gas; bloating r/t fermentation of carbs |
Non-sulfonylurea | Repaglinide/prandin, Nateglinide/starlix. Targets functioning beta cells in pancreas to stimulate short-term insulin secretion. Rapid onset (1hour peak), short duration (4hours). Reduces postprandial BG. Take 0-30min before meal, NO MEAL NO MED |
Repaglinide/prandin | Non-sulfonylurea. Targets functioning beta cells in pancreas to stimulate short-term insulin secretion. Rapid onset (1hour peak), short duration (4hours). Reduces postprandial BG. |
Nateglinide/starlix | Non-sulfonylurea. Targets functioning beta cells in pancreas to stimulate short-term insulin secretion. Rapid onset (1hour peak), short duration (4hours). Reduces postprandial BG. |
Non-sulfonylurea side effects | Hypoglycemia, moderate weight gain, caution in those with liver failure or on dialysis, adherence issues |
Created by:
kat10
Popular Nursing sets